

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the Claims

Please amend the claims as follows.

1. (Twice amended) A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain, or are associated with, an abnormal molecule or an abnormally elevated amount of a molecule and which cells are capable of presenting at least part of the molecule on their surface by [an] a particular HLA class I (or equivalent) molecule, the method comprising administering to the patient a therapeutically effective amount of cytotoxic T lymphocytes (CTL) which are selected to specifically recognize at least part of the molecule when presented by an HLA class I (or equivalent) molecule on the surface of a cell characterised in that the cytotoxic T lymphocytes are derived from an individual which individual does not carry the HLA class I (or equivalent) molecule type which, in the patient, presents at least part of the abnormal molecule[, or molecule abnormally elevated,] contained in, or associated with, the diseased cells of the patient or presents an abnormally elevated of the molecule contained in, or associated with, the diseased cells of the patient.

5. (Twice amended) A method according to Claim 4 wherein the polypeptide is a [mutuant] mutant polypeptide associated with the diseased cells.

Remarks

Claims 1-18, 20-43, and 45-49 are pending. Claims 1 and 5 have been amended. Claims 10-13, 20-43 and 45-49 have been withdrawn from consideration as being drawn to a non-elected invention. Claims 1 and 5 were amended to more clearly claim what applicants consider to be their invention. Claim 1 was amended to clarify that the cells of the patient either contain, or are associated with, an abnormal molecule or contain, **or** are associated with, an abnormally